Prognostic value of circulating Chromogranin A in prostate cancer: a systematic review and meta-analysis

BackgroundThere are discrepancies between the results of different studies regarding the prognostic role of circulating Chromogranin A (CgA) in prostate cancer. Therefore, we conducted a meta-analysis of the available findings to explore the value of circulating Chromogranin A in the prognosis of pr...

Full description

Saved in:
Bibliographic Details
Main Authors: Xiaoying Tang, Zhenyu Liu, Liangdong Song, Huixuan Zhu, Shuai Su, Delin Wang
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-02-01
Series:Frontiers in Oncology
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2025.1521558/full
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832540307489554432
author Xiaoying Tang
Zhenyu Liu
Liangdong Song
Huixuan Zhu
Shuai Su
Delin Wang
author_facet Xiaoying Tang
Zhenyu Liu
Liangdong Song
Huixuan Zhu
Shuai Su
Delin Wang
author_sort Xiaoying Tang
collection DOAJ
description BackgroundThere are discrepancies between the results of different studies regarding the prognostic role of circulating Chromogranin A (CgA) in prostate cancer. Therefore, we conducted a meta-analysis of the available findings to explore the value of circulating Chromogranin A in the prognosis of prostate cancer.MethodsWe systematically searched the PubMed, Embase, Web of Science, Cochrane Library, and Clinical Trials databases for studies on the relationship between CgA and survival outcomes in prostate cancer from inception until December 2024, and we focused on articles detecting circulating CgA, with the primary endpoints of the studies being overall survival (OS), and progression-free survival (PFS).ResultsOf the 2049 articles retrieved, 10 articles met our inclusion criteria, involving a total of 1445 patients. Elevated circulating CgA was associated with poorer OS (HR=1.82, 95% CI: 1.38–2.41; p<0.001) and PFS (HR=2.04, 95% CI: 1.42–2.94; p<0.001). However, no correlation was found between post-treatment circulating CgA changes and OS (HR=0.95, 95% CI: 0.66–1.37; p=0.767).ConclusionCirculating CgA is a predictive marker of poor survival outcomes in prostate cancer However, the sample size of the current study is small and larger studies are needed to further validate this in the future.
format Article
id doaj-art-2d2fbac3f793406db51c0856b98c9104
institution Kabale University
issn 2234-943X
language English
publishDate 2025-02-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Oncology
spelling doaj-art-2d2fbac3f793406db51c0856b98c91042025-02-05T05:17:39ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2025-02-011510.3389/fonc.2025.15215581521558Prognostic value of circulating Chromogranin A in prostate cancer: a systematic review and meta-analysisXiaoying TangZhenyu LiuLiangdong SongHuixuan ZhuShuai SuDelin WangBackgroundThere are discrepancies between the results of different studies regarding the prognostic role of circulating Chromogranin A (CgA) in prostate cancer. Therefore, we conducted a meta-analysis of the available findings to explore the value of circulating Chromogranin A in the prognosis of prostate cancer.MethodsWe systematically searched the PubMed, Embase, Web of Science, Cochrane Library, and Clinical Trials databases for studies on the relationship between CgA and survival outcomes in prostate cancer from inception until December 2024, and we focused on articles detecting circulating CgA, with the primary endpoints of the studies being overall survival (OS), and progression-free survival (PFS).ResultsOf the 2049 articles retrieved, 10 articles met our inclusion criteria, involving a total of 1445 patients. Elevated circulating CgA was associated with poorer OS (HR=1.82, 95% CI: 1.38–2.41; p<0.001) and PFS (HR=2.04, 95% CI: 1.42–2.94; p<0.001). However, no correlation was found between post-treatment circulating CgA changes and OS (HR=0.95, 95% CI: 0.66–1.37; p=0.767).ConclusionCirculating CgA is a predictive marker of poor survival outcomes in prostate cancer However, the sample size of the current study is small and larger studies are needed to further validate this in the future.https://www.frontiersin.org/articles/10.3389/fonc.2025.1521558/fullprostate cancercirculating Chromogranin Aneuroendocrinemeta-analysisprognostic
spellingShingle Xiaoying Tang
Zhenyu Liu
Liangdong Song
Huixuan Zhu
Shuai Su
Delin Wang
Prognostic value of circulating Chromogranin A in prostate cancer: a systematic review and meta-analysis
Frontiers in Oncology
prostate cancer
circulating Chromogranin A
neuroendocrine
meta-analysis
prognostic
title Prognostic value of circulating Chromogranin A in prostate cancer: a systematic review and meta-analysis
title_full Prognostic value of circulating Chromogranin A in prostate cancer: a systematic review and meta-analysis
title_fullStr Prognostic value of circulating Chromogranin A in prostate cancer: a systematic review and meta-analysis
title_full_unstemmed Prognostic value of circulating Chromogranin A in prostate cancer: a systematic review and meta-analysis
title_short Prognostic value of circulating Chromogranin A in prostate cancer: a systematic review and meta-analysis
title_sort prognostic value of circulating chromogranin a in prostate cancer a systematic review and meta analysis
topic prostate cancer
circulating Chromogranin A
neuroendocrine
meta-analysis
prognostic
url https://www.frontiersin.org/articles/10.3389/fonc.2025.1521558/full
work_keys_str_mv AT xiaoyingtang prognosticvalueofcirculatingchromograninainprostatecancerasystematicreviewandmetaanalysis
AT zhenyuliu prognosticvalueofcirculatingchromograninainprostatecancerasystematicreviewandmetaanalysis
AT liangdongsong prognosticvalueofcirculatingchromograninainprostatecancerasystematicreviewandmetaanalysis
AT huixuanzhu prognosticvalueofcirculatingchromograninainprostatecancerasystematicreviewandmetaanalysis
AT shuaisu prognosticvalueofcirculatingchromograninainprostatecancerasystematicreviewandmetaanalysis
AT delinwang prognosticvalueofcirculatingchromograninainprostatecancerasystematicreviewandmetaanalysis